Format

Send to

Choose Destination
BMC Infect Dis. 2014 Mar 26;14:166. doi: 10.1186/1471-2334-14-166.

Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series.

Author information

1
Department of Internal Medicine, Division of Experimental Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. mihai.netea@radboudumc.nl.

Abstract

BACKGROUND:

Invasive fungal infections are very severe infections associated with high mortality rates, despite the availability of new classes of antifungal agents. Based on pathophysiological mechanisms and limited pre-clinical and clinical data, adjunctive immune-stimulatory therapy with interferon-gamma (IFN-γ) may represent a promising candidate to improve outcome of invasive fungal infections by enhancing host defence mechanisms.

METHODS:

In this open-label, prospective case series, we describe eight patients with invasive Candida and/or Aspergillus infections who were treated with recombinant IFN-γ (rIFN-γ, 100 μg s.c., thrice a week) for 2 weeks in addition to standard antifungal therapy.

RESULTS:

Recombinant IFN-γ treatment in patients with invasive Candida and/or Aspergillus infections partially restored immune function, as characterized by an increased HLA-DR expression in those patients with a baseline expression below 50%, and an enhanced capacity of leukocytes from treated patients to produce proinflammatory cytokines involved in antifungal defence.

CONCLUSIONS:

The present study provides evidence that adjunctive immunotherapy with IFN-γ can restore immune function in fungal sepsis patients, warranting future clinical studies to assess its potential clinical benefit.

TRIAL REGISTRATION:

ClinicalTrials.gov--NCT01270490.

PMID:
24669841
PMCID:
PMC3987054
DOI:
10.1186/1471-2334-14-166
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center